Targeted Covalent Inhibition of <i>Plasmodium</i> FK506 Binding Protein 35
作者:Thomas C. Atack、Donald D. Raymond、Christa A. Blomquist、Charisse Flerida Pasaje、Patrick R. McCarren、Jamie Moroco、Henock B. Befekadu、Foxy P. Robinson、Debjani Pal、Lisl Y. Esherick、Alessandra Ianari、Jacquin C. Niles、William R. Sellers
DOI:10.1021/acsmedchemlett.0c00272
日期:2020.11.12
protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35
Synthesis and cdc25B inhibitory activity evaluation of chalcones
作者:Fei Zhao、Qing-Jie Zhao、Jing-Xia Zhao、Da-Zhi Zhang、Qiu-Ye Wu、Yong-Sheng Jin
DOI:10.1007/s10600-013-0563-7
日期:2013.5
A library of sixty-five chalcones was prepared for screening against the protein phosphatase, cdc25B. From this library, thirteen compounds were found having good inhibitory activity. Two compounds have excellent activity and can be used for the design of more potent antiproliferative agents.
2-Substituted-4-quinolones 2 and the corresponding 2,3-dihydro-2-substituted-4-quinolones 3 have been obtained by reduction with CO at 170 °C and 30 atm of 2-nitrochalcones 1, catalysed by Ru3(CO)12 with DIAN-Me as co-catalyst in ethanol–water.